Mar 2, 2026 | Gilead’s $7.8B CAR-T Bet, YUVIWEL Approved, PADCEV-Keytruda Resets Bladder Cancer

from The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus · host BZ Group

Gilead acquires Arcellx for $7.8B to challenge J&J’s Carvykti in multiple myeloma with a December FDAdecision approaching. Both Friday decisions resolved: YUVIWEL wins accelerated approval as the first weekly achondroplasia treatment, Dupixent adds AFRS toits ENT franchise. PADCEV plus Keytruda delivers a 47% recurrence reduction in muscle-invasive bladder cancer. CagriSema analyst downgrades continue, and theMarch 20th Rhythm decision could reshape the obesity landscape.

Episode metadata supplied by the publisher feed · Published Mar 3, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

Mar 2, 2026 | Gilead’s $7.8B CAR-T Bet, YUVIWEL Approved, PADCEV-Keytruda Resets Bladder Cancer

0:00 10:18

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus?

This episode is 10 minutes long.

When was this The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus episode published?

This episode was published on March 3, 2026.

Can I download this The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!